Page last updated: 2024-12-11

spirilloxanthin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

spirilloxanthin : A carotenoid ether that is (3E,3'E)-1,1'-dihydroxy-3,3',4,4'-tetradehydro-1,1',2,2'-tetrahydro-psi,psi-carotene in which both hydroxyl hydrogens are replaced by methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5366506
CHEBI ID35328
SCHEMBL ID504505
MeSH IDM0155659

Synonyms (26)

Synonym
LMPR01070122
NSC633983 ,
(3e,3'e)-1,1'-dimethoxy-3,3',4,4'-tetradehydro-1,1',2,2'-tetrahydro-psi,psi-carotene
(4e,6e,8e,10e,12e,14e,16e,18e,20e,22e,24e,26e,28e)-2,31-dimethoxy-2,6,10,14,19,23,27,31-octamethyl-dotriaconta-4,6,8,10,12,14,16,18,20,22,24,26,28-tridecaene
34255-08-8
spirilloxanthin
rhodoviolascin
(4e,6e,8e,10e,12e,14e,16e,18e,20e,22e,24e,26e,28e)-2,31-dimethoxy-2,6,10,14,19,23,27,31-octamethyldotriaconta-4,6,8,10,12,14,16,18,20,22,24,26,28-tridecaene
unii-p2or1d365y
psi,psi-carotene, 3,3',4,4'-tetradehydro-1,1',2,2'-tetrahydro-1,1'-dimethoxy-
p2or1d365y ,
CHEBI:35328
3,3',4,4'-tetradehydro-1,1',2,2'-tetrahydro-1,1'-dimethoxy-psi,psi-carotene
lycopene, 3,3',4,4'-tetradehydro-1,1',2,2'-tetrahydro-1,1'-dimethoxy-, all-trans-
all-trans-spirilloxanthin
rhodoviolascin, all-trans-
spirilloxanthin, all-trans-
.psi.,.psi.-carotene, 3,3',4,4'-tetradehydro-1,1',2,2'-tetrahydro-1,1'-dimethoxy-
all-trans-rhodoviolascin
rhodoviolascin [mi]
SCHEMBL504505
VAZQBTJCYODOSV-HZUCFJANSA-N
3,3',4,4'-tetradehydro-1,1',2,2'-tetrahydro-psi,psi-carotene, 1,1'-dimethoxy-
rhodouiolascin, all-trans-
Q27116457
DTXSID001316989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
carotenoid ether
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
spirilloxanthin and 2,2'-diketo-spirilloxanthin biosynthesis515

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (10.87)18.7374
1990's2 (4.35)18.2507
2000's13 (28.26)29.6817
2010's25 (54.35)24.3611
2020's1 (2.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.38 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]